MicroMedicine to introduce new white blood cell isolation technology at SITC annual conference

Filed under: Pharma Industry News | Tags: , , , , , ,

MicroMedicine, a US life sciences technology company, will launch Sorterra Cell Isolation System, a white blood cell isolation technology, at the 34th Society for Immunotherapy of Cancer (SITC) annual conference to be held from November 6-10 in National Harbour, Maryland.

Sorterra Cell Isolation System will separate white blood cells from human peripheral blood preserving sample integrity.

Developed for the purposes of research and clinical applications, the new automated system leverages MicroMedicine’s patented microfluidic channels without centrifugation or labeling procedure.

Microfluidics-based Sorterra will reportedly yield 30% more lymphocytes compared to density gradient methods, >99.9% red blood cell and platelet removal, and a >98% viability of white blood cells.

MicroMedicine to introduce new white blood cell isolation technology at SITC annual conference

MicroMedicine to introduce new white blood cell isolation technology at SITC annual conference. Photo courtesy of Arek Socha from Pixabay.

Dr. John Powderly – founder of Carolina BioOncology Institute and an early adopter of the Sorterra system, said: “Our team has worked meticulously and tirelessly on improving and perfecting the separation process and we’re thrilled with the results.

“The system recovers twice as many cells in half the time, leading to less input blood required to conduct the downstream assays and significant time savings.”

Founded at Massachusetts General Hospital in 2015, MicroMedicine’s patented microfluidic platform can be utilized for multiple applications, including cell isolation, cell concentration, and fluid exchange.

The SITC, a nonprofit organization, advances the development, science and application of cancer immunotherapy and tumor immunology to improve cancer patient outcomes.

Headquartered in Huntersville, North Carolina, Carolina BioOncology Institute focuses on Phase I clinical trials for immunotherapy-based cancer treatments and consists of a Human Applications Laboratory to develop personalized cellular immunotherapy cancer medicine.

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *